NASDAQ:HBIO

Harvard Bioscience Stock Forecast, Price & News

$6.71
-0.12 (-1.76 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.57
Now: $6.71
$6.89
50-Day Range
$3.91
MA: $5.81
$6.99
52-Week Range
$2.06
Now: $6.71
$7.14
Volume136,970 shs
Average Volume215,544 shs
Market Capitalization$267.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
Harvard Bioscience logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
Current SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999
Employees428
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$116.18 million
Cash Flow$0.54 per share
Book Value$2.15 per share

Profitability

Net Income$-4,690,000.00

Miscellaneous

Market Cap$267.91 million
Next Earnings Date5/6/2021 (Confirmed)
OptionableOptionable

Headlines

See More Headlines

MarketRank

Overall MarketRank

1.82 out of 5 stars

Computer And Technology Sector

143rd out of 1,547 stocks

Analytical Instruments Industry

3rd out of 29 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
$6.71
-0.12 (-1.76 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

Is Harvard Bioscience a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Harvard Bioscience stock.
View analyst ratings for Harvard Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Harvard Bioscience?

Wall Street analysts have given Harvard Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harvard Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Harvard Bioscience
.

How can I listen to Harvard Bioscience's earnings call?

Harvard Bioscience will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its quarterly earnings results on Tuesday, March, 9th. The medical instruments supplier reported $0.08 EPS for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.04. The medical instruments supplier earned $30.98 million during the quarter, compared to analysts' expectations of $27.15 million. Harvard Bioscience had a negative net margin of 6.51% and a positive trailing twelve-month return on equity of 4.29%.
View Harvard Bioscience's earnings history
.

How has Harvard Bioscience's stock been impacted by COVID-19?

Harvard Bioscience's stock was trading at $2.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HBIO stock has increased by 171.7% and is now trading at $6.71.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for HBIO?

3 equities research analysts have issued 1 year target prices for Harvard Bioscience's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Harvard Bioscience's share price to reach $9.00 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts' price targets for Harvard Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:
  • Mr. James W. Green, Pres, CEO & Chairman (Age 63, Pay $594.19k)
  • Mr. Michael A. Rossi, Chief Financial Officer (Age 47, Pay $321.2k)
  • Mr. Kenneth Fletcher Olson, Chief Operating Officer (Age 59)
  • Mr. Jacques Coumans Ph.D., Chief Marketing Officer
  • David Sirois, Director of Corp. Accounting & SEC Reporting

Who are some of Harvard Bioscience's key competitors?

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (0.22%) and Wedge Capital Management L L P NC (0.20%). Company insiders that own Harvard Bioscience stock include Alan I Edrick, Bertrand Loy, James W Green, Katherine A Eade, Thomas W Loewald and Value Fund Lp Palogic.
View institutional ownership trends for Harvard Bioscience
.

Which major investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., and Wedge Capital Management L L P NC.
View insider buying and selling activity for Harvard Bioscience
or view top insider-selling stocks.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $6.71.

How much money does Harvard Bioscience make?

Harvard Bioscience has a market capitalization of $267.91 million and generates $116.18 million in revenue each year. The medical instruments supplier earns $-4,690,000.00 in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 428 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is www.harvardbioscience.com.

Where are Harvard Bioscience's headquarters?

Harvard Bioscience is headquartered at 84 OCTOBER HILL RD, HOLLISTON MA, 01746.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.